Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | DGKA | P23743 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18266869 | 0.94 | ALDH1A1 (0.55) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL11877869 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL14449519 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL8772076 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL17123130 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL14213382 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL12092477 | 0.92 | TSHR (0.52) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL714030 | 0.92 | TSHR (0.52) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL17123126 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 | |
| SCHEMBL17123133 | 0.92 | DGKA (0.74) | TSHRDGKAALDH1A1LMNAPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541057-B2 | Cyclohexane oxidation process byproduct derivatives and methods for using the same | INVISTA NORTH AMERICA S.A R.L. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101009-A1 | CYCLOHEXANE OXIDATION PROCESS BYPRODUCT STREAM DERIVATIVES AND METHODS FOR USING THE SAME | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120064252-A1 | CYCLOHEXANE OXIDATION PROCESS BYPRODUCT DERIVATIVES AND METHODS FOR USING THE SAME | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010071761-A1 | CYCLOHEXANE OXIDATION PROCESS BYPRODUCT STREAM DERIVATIVES AND METHODS FOR USING THE SAME | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071759-A1 | CYCLOHEXANE OXIDATION PROCESS BYPRODUCT DERIVATIVES AND METHODS FOR USING THE SAME | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101009-A1 | CYCLOHEXANE OXIDATION PROCESS BYPRODUCT STREAM DERIVATIVES AND METHODS FOR USING THE SAME | DECR1, SIGMAR1, NOP2 | TSHR 4661/4885DGKA 1104/4885ALDH1A1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.